Hyperleptinemia as a Component of a Metabolic Syndrome of Cardiovascular Risk
- 1 June 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 18 (6) , 928-933
- https://doi.org/10.1161/01.atv.18.6.928
Abstract
Abstract —In humans, production of the adipocyte-derived peptide leptin has been linked to adiposity, insulin, and insulin sensitivity. We therefore considered that alterations in plasma leptin concentrations could constitute an additional component of a metabolic syndrome of cardiovascular risk. To explore this hypothesis, we employed factor analysis, a multivariate statistical technique that allows reduction of large numbers of highly intercorrelated variables to composite, biologically meaningful factors. Seventy-four men [age, 48.4±1.3 years (mean±SEM); body mass index (BMI), 25.6±0.3 kg/m 2 ] who were free of coronary heart disease and diabetes underwent anthropometric measurements (subscapular-to-triceps [S:T] and subscapular-to-biceps [S:B] skinfold thickness ratios, measurement of fasting plasma leptin, and an intravenous glucose tolerance test (IVGTT) for assessment of insulin sensitivity. Plasma leptin concentrations were correlated with BMI ( r =0.57, P r =0.34, P =0.003), S:B ( r =0.37, P r =0.24, P =0.044), fasting triglycerides ( r =0.31, P =0.007), serum uric acid ( r =0.35, P =0.003), fasting glucose ( r =0.32, P =0.003) and insulin ( r =0.33, P =0.004), and IVGTT insulin ( r =0.63, P r =−0.32, P =0.006). No significant correlations emerged between plasma leptin concentrations and age, high density lipoprotein cholesterol, or IVGTT glucose. In multivariate regression analyses, BMI (standardized coefficient [SC] =0.40, P =0.001), fasting insulin (SC=0.23, P =0.036), and IVGTT insulin (SC=0.51, P R 2 =0.56, P P R 2 =0.45, P <0.001). Factor analysis of plasma leptin concentrations and the variables that are considered relevant to the insulin resistance syndrome revealed a clustering of plasma leptin concentrations with a factor dominated by insulin resistance and high IVGTT insulin, separate from a high IVGTT glucose/central obesity factor and a high triglyceride/low high density lipoprotein cholesterol factor. Together, these factors accounted for 55.9% of the total variance in the dataset. In conclusion, interindividual variations in plasma leptin concentrations are strongly related to the principal components of the insulin resistance syndrome. Further studies are needed to determine whether the insulin-leptin axis plays a coordinating role in this syndrome and whether plasma leptin concentrations could provide an additional measure of cardiovascular risk.Keywords
This publication has 25 references indexed in Scilit:
- Leptin concentrations and insulin sensitivity in normoglycemic menInternational Journal of Obesity, 1997
- Functional Antagonism between CCAAT/Enhancer Binding Protein-α and Peroxisome Proliferator-activated Receptor-γ on the Leptin PromoterPublished by Elsevier ,1997
- Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.Journal of Clinical Investigation, 1996
- Down-regulation of the Expression of the Obese Gene by an Antidiabetic Thiazolidinedione in Zucker Diabetic Fatty Rats and db/db MiceJournal of Biological Chemistry, 1996
- Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects.Journal of Clinical Investigation, 1996
- Transient increase in obese gene expression after food intake or insulin administrationNature, 1995
- Positional cloning of the mouse obese gene and its human homologueNature, 1994
- Declaring independence: why we should be cautious.Journal of Epidemiology and Community Health, 1990
- Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 YearsBritish Journal of Nutrition, 1974
- Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogenJournal of Clinical Pathology, 1969